- Evogene (NASDAQ: EVGN ) reported third quarter EPS of $-1.310, $0.30 worse than the analyst estimate of $-1.010. Revenue for the quarter came in at $1.8M versus the consensus estimate of $2.85M.

Evogene's stock price closed at $1.65. It is down -57.470% in the last 3 months and down -72.650% in the last 12 months.

Evogene saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Evogene's stock price’s past reactions to earnings here .

According to InvestingPro , Evogene's Financial Health score is " fair performance ".

Check out Evogene's recent earnings performance , and Evogene's financials here .

Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar